Sir,

A 54-year-old gentleman with recurrence of supraglottic carcinoma larynx presented to us with papulosquamous lesions on the trunk and extremities noted 11 days after third dose of immunotherapy with nivolumab. He was started on IV nivolumab 100 mg biweekly after total laryngectomy. Eleven days after immunotherapy, he developed erythematous pruritic papulosquamous lesions. Historically, he had chronic plaque psoriasis 5 years prior which was in remission. There was no new onset joint pain. Cutaneous examination revealed symmetrically located bright erythematous scaly papules and plaques in a generalized distribution \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\]. Finger nails showed pitting and distal onycholysis \[[Figure 3](#F3){ref-type="fig"}\]. Scalp was not involved. A clinical diagnosis of psoriasis was made based on the past history of psoriasis, classical appearance of scaly erythematous plaques on the extensor aspect of extremities, trunk, palms, and soles along with characteristic nail changes such as pitting and onycholysis. Nivolumab was discontinued for a week and the patient was started on acitretin 25 mg once daily along with NBUVB phototherapy for psoriasis. Subsequently, nivolumab was restarted after 1 week as there was no further worsening of cutaneous symptoms and the treatment for psoriasis continued. At follow-up after 1month he had significant improvement with phototherapy and acitretin.

![Symmetrically distributed scaly papules and plaques in a generalized distribution](IDOJ-11-261-g001){#F1}

![Bright erythematous scaly plaques distributed symmetrically on both soles](IDOJ-11-261-g002){#F2}

![Pitting and distal onycholysis of finger nails](IDOJ-11-261-g003){#F3}

Psoriasis can be induced or exacerbated by PD-1 inhibitors.\[[@ref1]\] A study done on 21 patients with anti-PD-1-induced psoriasis found that the timeline to develop psoriasis was shorter if the patients had a previous psoriasis.\[[@ref2]\] Although stress can aggravate psoriasis, there are no reports of psoriatic flare due to underlying carcinoma larynx. Our patient developed skin lesions 11 days after the third dose of immunotherapy, demonstrating a temporal correlation between immunotherapy and recurrence of psoriasis. A histopathological examination was deferred in this case as the clinical picture was classical of psoriasis and only nonclassical or refractory cases are usually biopsied.\[[@ref3]\] The pathogenesis of psoriasis is widely debated and currently it is well known that interleukin-17 (IL-17) and IL-22 produced by T helper (Th) 17 cells play pivotal roles in the pathogenesis.\[[@ref4]\]

Studies have shown that blockade of immune-checkpoint receptors such as PD-1 and cytotoxic T-lymphocyte antigen-4 by its antibodies augment the helper T cell type 1 (Th1) and Th17 cell activities, correlating with antitumor efficacy and exacerbation of psoriasis.\[[@ref1][@ref4]\] New-onset psoriasis do not usually relapse after discontinuing immunotherapy. In a phase 1b study, other cutaneous adverse effects that were reported in 31% patients include a rash (12%), pruritus (9%), and vitiligo (3%).\[[@ref2]\] Photosensitivity, acneiform, and lichenoid eruptions have also been reported.\[[@ref1][@ref2]\] Inspite of the cutaneous flare, our patient had a regression of the malignancy correlating with the antitumor efficacy of nivolumab. A personal or family history of preexisting psoriasis should be asked for before initiation of immune checkpoint inhibitors. This will prompt the early diagnosis and management of psoriasis in such patients. We would like to highlight that psoriasis may be induced or worsened by immune checkpoint inhibitors, but this can be managed by standard therapy without significant interruption of immunotherapy.
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